National Cancer Institute (NCI)s

National Cancer Institute (NCI)

470 Protocols (265 Active Accrual of new subjects, 205 Follow-up of previously enrolled subjects)

 001961-C:

A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774

 001886-C:

A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

 001808-C:

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab after First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer

 001776-C:

A Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

 001771-C:

EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors (A ComboMATCH Treatment Trial)

 001770-C:

Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers

 001756-C:

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

 001749-C:

ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors

 001733-C:

A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

 001732-C:

A Phase 1 Study of the Polymerase Theta (POL-Theta) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors

 001713-C:

A Phase II Trial of Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer

 001665-C:

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

 001662-C:

A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction with a Vaccine Directed Against these Antigens in Participants with Metastatic Cance

 001620-C:

Pilot Prospective Study for PET-CT Imaging in Participants with Relapsed/Refractory Acute Leukemias

 001590-C:

Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab

 001578-C:

A Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

 001572-C:

A Phase II Study of Bevacizumab in Adults with Recurrent Respiratory Papillomatosis (RRP)

 001567-C:

Observational Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy

 001563-C:

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

 001556-C:

Phase II Trial of Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) without Testosterone Lowering Therapy

 001552-C:

Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors

 001549-C:

Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects with BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

 001548-C:

A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination with Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects with Biliary Tract Carcinoma (BTC)

 001547-C:

A First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

 001544-C:

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with Entinostat and Nivolumab as Adjuvant Therapy following Chemoradiation Therapy with or without Surgery for Locally Advanced Esophageal Cancer

 001542-C:

Phase Ib Study of Imatinib to Increase RUNX1 Activity in Participants with Germline RUNX1 Deficiency

 001541-C:

A Phase I/II Trial of Eltanexor (KPT-8602) with Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

 001538-C:

A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma and Multicentric Castleman Disease

 001536-C:

Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 with Pembrolizumab before Standard Treatment in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal Cancer

 001534-C:

Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors containing MYC or MYCN Amplifications

 001531-C:

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation with JSP191-Based Conditioning in Participants with GATA2 Deficiency

 001525-C:

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma

 001524-C:

A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies

 001523-C:

A Phase II Study of Lurbinectedin with or without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

 001516-C:

Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer

 001109-C:

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

 001099-C:

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that

 001092-C:

Exploring the Role of Palliative Care in Phase 1 Enrolled Pediatric Oncology Patients

 001056-C:

Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

 001004-C:

A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature(R) Status

 000975-C:

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples from Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

 000958-C:

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

 000930-C:

A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer

 000860-C:

A Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

 000792-C:

A Pilot Trial to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following CAR T-cell Induced Remission in Pediatric Patients with B Lineage Acute Lymphoblastic Leukemia

 000783-C:

Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilumumab in solid tumors

 000732-C:

A Long-Term Follow-Up Study of Patients Who Received VOR33

 000731-C:

A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation

 000726-C:

A Randomized Phase 2 Study of Atezolizumab with or without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)

 000696-C:

A Phase III, Multicenter, International Study with a Parallel, Randomized, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiform Neurofibr

 000692-C:

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide

 000678-C:

Rare Tumors and Cancer Predisposition in Individuals and Families

 000666-C:

A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

 000661-C:

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult Myelodysplastic Syndromes (MDS)

 000657-C:

Acceptance and Commitment Therapy for Caregivers of Children with a RASopathy: An Internal Pilot Feasibility Study and Follow-up Phase III Randomized Controlled Trial

 000643-C:

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

 000633-C:

Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

 000628-C:

A Study of Prospective Monitoring of Subjects with Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL

 000613-C:

Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood St

 000611-C:

A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer

 000596-C:

Phase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell Carcinoma

 000580-C:

A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2(alpha) Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinom

 000569-C:

Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy

 000520-C:

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

 000509-C:

An Open Label, Multi-Center Roll-Over Study to Assess Long-Term Safety in Patients Who are Ongoing or Have Completed a Prior Global Novartis or GSK Sponsored Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Study and are Judged by the Investigator to B

 000491-C:

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

 000489-C:

Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies

 000481-C:

Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

 000475-C:

Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)

 000473-C:

A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma

 000462-C:

Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma

 000423-C:

Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults with Sickle Cell Disease (SCD): A Pilot Randomized Controlled Trial

 000404-C:

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

 000359-C:

Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies

 000354-C:

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

 000337-C:

Natural History Study of KSHV-Associated Multicentric Castleman's Disease

 000328-C:

Bicalutamide Implants (Biolen ) with Radiation Therapy in Patients with Localized Prostate Cancer

 000324-C:

Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

 000317-C:

A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma

 000307-C:

Phase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

 000303-C:

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide Vs. Temozolomide and Olaparib For Advanced Pheochromocytoma And Paraganglioma

 000302-C:

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

 000277-C:

Imaging and Biopsy of People with HIV-1 Undergoing Analytic Treatment Interruption

 000274-C:

Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

 000264-C:

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

 000254-C:

A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

 000251-C:

The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

 000237-C:

Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

 000194-C:

A Phase I Trial of ProAgio, an anti- alpha-v-beta3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

 000178-C:

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

 000176-C:

A Phase I/II Trial of Lurbinectedin with Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers

 000144-C:

A Phase I/II Study of Sacituzumab Govitecan plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

 000114-C:

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated with Androgen Deprivation Therapy

 000103-C:

A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

 000096-C:

A Phase II study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK cells plus Pembrolizumab plus N-803 for Subjects with Recurrent/Metastatic Gastric or Head and Neck Cancer

 000085-C:

Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients: An Observational Study

 000080-C:

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

 000048-C:

A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer

 000045-C:

A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and other KK-LC-1 Positive Epithelial Cancers

 22-C-0005:

Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer

Next 100 Protocols